Alligator Bioscience’s CEO on the rights issue
Alligator Bioscience is developing tumour-directed antibody-based treatments against cancer. At the beginning of the year, the company reported positive interim results from the OPTIMIZE-1...
BioStock Investor Pitch: Alligator Bioscience
Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic...
Clinical Trial Investigator in Chordate’s study in chronic migraine
Chordate Medical's patient study PM007 is completed and the results indicate that Kinetic Oscillation Stimulation is an effective and safe treatment for chronic migraine....
Interview with Synact Pharma about the changes in the company
Biotech company Synact Pharma visited BioStock's studio to talk about changes in the management and board. With upcoming phase II data during the autumn...
BioStock Investor Pitch: ExpreS2ion Biotechnologies
Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest pipeline addition, the cytomegalovirus. The...
Xintela’s chairman about the company’s journey
Gregory Batcheller has been the chairman of biopharma Xintela since 2011. During this time he has seen the company reach several milestones and now...
WntResearch’s CEO on the option program and the NeoFox study
The development company WntResearch is currently in the process of redeeming the TO5 warrant. The capital injection is made to continue the phase IIb...
Expert Insights: Aqilion’s CEO on dealmaking
Aqilion's CEO Sarah Fredriksson participated at the Expert Insights session of the BioStock Investor Meeting. During the interview, she discussed the company's recent deal...
Update from Arcede Pharma CEO
Arcede Pharma develops RCD405, a dual-action drug candidate for the treatment of COPD and severe asthma. The company is underway with the final part...
Chordate’s CEO on entering new markets
How does Chordate Medical's treatment for rhinitis and chronic migraine work? What market interest has the company seen and what strategy is it working...
